Cargando…

Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine

Cediranib is an orally available, pan-VEGFR tyrosine kinase inhibitor. A previous Phase III study of patients with recurrent glioblastoma treated with this drug did not meet the primary end of progressive-free survival (PFS). We identified one patient, a 57-year-old Caucasian female who, following s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drazin, Doniel, Al-Khouja, Lutfi, Patel, Ashish, Hu, Jethro, Phuphanich, Surasak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2016
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757029/ https://www.ncbi.nlm.nih.gov/pubmed/26929887 http://dx.doi.org/10.7759/cureus.460

Ejemplares similares

Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis
por: Ren, Xing, et al.
Publicado: (2021)

The Effects of the 80-hour Workweek on Occupational Hazards
por: Drazin, Doniel, et al.
Publicado: (2016)

Economics of image guidance and navigation in spine surgery
por: Al-Khouja, Lutfi, et al.
Publicado: (2015)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

Treatment of Recurrent Disc Herniation: A Systematic Review
por: Drazin, Doniel, et al.
Publicado: (2016)

Post-irradiation lumbosacral radiculopathy associated with multiple cavernous malformations of the cauda equina: Case report and review of the literature
por: Drazin, Doniel, et al.
Publicado: (2017)

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
por: Brown, Nicholas, et al.
Publicado: (2016)

ET-02 EFFICACY OF THE SALVAGE THERAPY VIA LOMUSTINE AND NIMUSTINE FOR RECURRENT GLIOBLASTOMA WITH TEMOZOLOMIDE RESISTANCE
por: Yamamuro, Shun, et al.
Publicado: (2019)

Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis
por: Song, Jie, et al.
Publicado: (2018)

Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines
por: Fishman, Hila, et al.
Publicado: (2023)

Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial
por: Patil, Vijay M., et al.
Publicado: (2022)

Spine Surgery in the Octogenarian Population: A Comparison of Demographics, Surgical Approach, and Healthcare Utilization With the PearlDiver Database
por: Kumar, Chitra D, et al.
Publicado: (2021)

Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro
por: Kapteijn, Maaike Y., et al.
Publicado: (2023)

Epithelioid Hemangioendothelioma of the Mastoid: Resection for Recurrence and Adjuvant Radiation with 8-Year Followup
por: Drazin, Doniel, et al.
Publicado: (2013)

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
por: Rosenthal, Mark, et al.
Publicado: (2020)

Association of Intracranial Aneurysms with Meningiomas, Pituitary Adenomas, and Gliomas: Review of Possible Interrelationships
por: Spitler, Kevin, et al.
Publicado: (2013)

Public awareness of the bone morphogenic protein controversy: Evidence from news publications
por: Drazin, Doniel, et al.
Publicado: (2014)

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
por: Beije, N, et al.
Publicado: (2015)

Adult Brainstem Glioblastoma Multiforme: Long-term Survivor
por: Barnard, Zachary R, et al.
Publicado: (2015)

Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance
por: Yamamuro, Shun, et al.
Publicado: (2021)

Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
por: Gopinathan, Ganga, et al.
Publicado: (2022)

Honokiol in glioblastoma recurrence: a case report
por: Wang, Ce, et al.
Publicado: (2023)

CLRM-04. PHASE I/II SAFETY AND EFFICACY STUDY OF BET BROMODOMAIN INHIBITOR OTX-015 WITH OLAPARIB AND LOMUSTINE IN PATIENTS WITH RECURRENT GLIOBLASTOMA
por: Lam, Fred
Publicado: (2021)

Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas
por: Kim, Young-Joo, et al.
Publicado: (2015)

Lomustine Loaded Superparamagnetic Iron Oxide Nanoparticles Conjugated with Folic Acid for Treatment of Glioblastoma Multiforma (GBM)
por: Jafari, Salman, et al.
Publicado: (2020)

Lung toxicity of lomustine in the treatment of progressive gliomas
por: Seliger, Corinna, et al.
Publicado: (2022)

Smartphone use in neurosurgery? APP-solutely!
por: Zaki, Michael, et al.
Publicado: (2014)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
por: Bi, Jianling, et al.
Publicado: (2021)

Development of Lomustine and n-Propyl Gallate Co-Encapsulated Liposomes for Targeting Glioblastoma Multiforme via Intranasal Administration
por: Katona, Gábor, et al.
Publicado: (2022)

Call-Fleming Syndrome (Reversible Cerebral Artery Vasoconstriction) and Aneurysm Associated with Multiple Recreational Drug Use
por: Drazin, Doniel, et al.
Publicado: (2013)

Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2020)

Vertebral Column Metastases from an Esthesioneuroblastoma: Chemotherapy, Radiation, and Resection for Recurrence with 15-Year Followup
por: Shirzadi, Ali S., et al.
Publicado: (2013)

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy
por: Spencer, S K M, et al.
Publicado: (2013)

Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
por: Lu, Guangrong, et al.
Publicado: (2019)

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
por: Nguyen, James, et al.
Publicado: (2023)

Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
por: Tremont-Lukats, Ivo W., et al.
Publicado: (2019)

Clinical feasibility of modified procarbazine and lomustine chemotherapy without vincristine as a salvage treatment for recurrent adult glioma
por: Ahn, Stephen, et al.
Publicado: (2022)

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
por: Andronesi, Ovidiu C., et al.
Publicado: (2017)

NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma
por: Batchelor, Tracy T, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p34hneevc7ne9j1p9ga71iqmdv